Anthony Ian Walker

Onyvax Ltd. developed cancer remedy therapies. The company was founded in 1995 and was headquartered in Bradford, the United Kingdom.

Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA.

Part of International Business Machines Corp., Wilkerson Group is a consulting company that provides services to the pharmaceutical and medical products industry. The company is based in New York, NY. The company was founded by Kenneth D. Noonan. The CEO is Neil MacAllister. Wilkerson Group was acquired by International Business Machines Corp. on April 01, 1996.

Alacrita LLP is an expertise-based consulting firm that offers consulting support on a range of R&D and business issues to biotech and pharma companies, academic institutions, and healthcare investors. Alacrita was founded in 2009 by Anthony Ian Walker and is based in London, UK. The British company conducts more than 250 successful client assignments every year and has a broad network of specialized consultants who can be engaged as necessary when additional, specialized expertise is required. Its core team leverages a consulting network of 250+ functional specialists, all with at least 20 years of pharmaceutical industry experience, allowing it to offer a versatile combination of depth and breadth in expertise that is unrivaled in the industry and that can be precisely tailored to the needs of each client.

SBI JI Innovation Advisory Ltd (SBI JI Innovation Advisor) is a venture capital firm founded in 2017. The firm is headquartered in Tel Aviv-Yafo, Israel.

Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023.